Please login to the form below

Not currently logged in
Email:
Password:

Nabriva Therapeutics appoints new chief commercial officer

Francesco Maria Lavino joins to support commercialisation of its new antibiotic

Bacterial infections focussed Nabriva Therapeutics has appointed Francesco Maria Lavino as its chief commercial officer ahead of the group’s phase III clinical trial for lefamulin - a potential new treatment for community-acquired bacterial pneumonia.

Lavino joins the Austrian clinical-stage biopharma firm from Merck & Co (MSD), bringing nearly two decades of pharmaceutical sales and marketing experience with expertise in anti-infective medications.

He said: “Nabriva Therapeutics is poised to introduce what is potentially the first new class of antibiotics for systemic human use in nearly two decades.

“I am looking forward to working with the management team to address serious medical needs in lung, skin and potentially other types of infections.”

Prior to serving MSD as its acting vice president, global brand leader anti-infective portfolio, he was vice president, international marketing for the anti-infectives portfolio at Cubist Pharmaceuticals. He has also held roles at UCB Pharma and 3M in Italy.

Colin Broom, chief executive officer of Nabriva, said: “Francesco has the right experience and leadership qualities to build out a fully integrate commercial team and hospital field force in the US, and I am delighted to welcome him as part of our team.”

20th July 2017

From: Sales

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Fishawack Group of Companies

The Fishawack Group of Companies is one of the largest independent medical communications and medical marketing specialists, with teams in...

Latest intelligence

Mistrust in medical research: a patient perspective
The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the...
Real-world evidence: breaking boundaries in rare disease
Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and...
The heavy toll of COVID-19 on cancer patients
We all know that finding and treating cancer early saves lives. During the COVID-19 pandemic, oncology treatments paused while cancer continued to spread. So, what has been the impact of...

Infographics